A phase 1 study of the safety, reactogenicity, and immunogenicity of a Schistosoma mansoni vaccine with or without glucopyranosyl lipid A aqueous formulation (GLA-AF) in healthy adults from a non-endemic area

BACKGROUND: Schistosomiasis caused by Schistosoma mansoni (Sm) is a chronic, debilitating and potentially deadly neglected tropical disease. The licensure of a vaccine to prevent schistosomiasis would represent a major breakthrough in public health. METHODS: The safety and immunogenicity of a candid...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:Vaccine
Main Authors: Keitel, W.A., Potter, G.E., Diemert, D., Bethony, J., El Sahly, H.M., Kennedy, J.K., Patel, S.M., Plieskatt, J.L., Jones, W., Deye, G., Bottazzi, M.E., Hotez, P.J., Atmar, R.L.
Formato: Artigo
Idioma:Inglês
Publicado em: 2019
Assuntos:
Article
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC6771426/
https://ncbi.nlm.nih.gov/pubmed/31515141
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.vaccine.2019.08.075
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados